Zacks Investment Research lowered shares of Edap Tms (NASDAQ:EDAP) from a buy rating to a hold rating in a research report released on Tuesday morning.

According to Zacks, “EDAP TMS S.A. develops, produces, markets and distributes minimally invasive medical devices, primarily for the treatment of urological diseases. They currently produce and market devices for treatment of benign prostate hyperplasia and urinary tract stones. They are also developing a third range of products for minimally invasive destruction of certain types of tumors. “

A number of other brokerages have also recently commented on EDAP. ValuEngine raised Edap Tms from a sell rating to a hold rating in a research report on Friday, October 6th. HC Wainwright reaffirmed a buy rating and set a $6.50 price target on shares of Edap Tms in a research report on Monday, October 9th.

Shares of Edap Tms (EDAP) traded up $0.01 during trading hours on Tuesday, reaching $2.71. The company’s stock had a trading volume of 69,000 shares, compared to its average volume of 42,000. The company has a market cap of $78.10, a P/E ratio of -33.88 and a beta of 1.02. The company has a debt-to-equity ratio of 0.11, a current ratio of 2.96 and a quick ratio of 2.35. Edap Tms has a 52-week low of $2.25 and a 52-week high of $3.85.

Edap Tms (NASDAQ:EDAP) last issued its quarterly earnings results on Wednesday, November 15th. The medical equipment provider reported ($0.02) EPS for the quarter, meeting analysts’ consensus estimates of ($0.02). Edap Tms had a positive return on equity of 7.85% and a negative net margin of 5.36%. The firm had revenue of $8.44 million for the quarter, compared to analysts’ expectations of $11.05 million. The business’s quarterly revenue was down 5.6% compared to the same quarter last year. sell-side analysts forecast that Edap Tms will post -0.01 EPS for the current year.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Virtu KCG Holdings LLC purchased a new position in shares of Edap Tms during the 2nd quarter valued at $117,000. Archon Capital Management LLC lifted its position in shares of Edap Tms by 12.5% during the 3rd quarter. Archon Capital Management LLC now owns 843,489 shares of the medical equipment provider’s stock valued at $2,514,000 after buying an additional 93,762 shares during the last quarter. Finally, Essex Investment Management Co. LLC lifted its position in shares of Edap Tms by 520.2% during the 3rd quarter. Essex Investment Management Co. LLC now owns 323,528 shares of the medical equipment provider’s stock valued at $964,000 after buying an additional 271,367 shares during the last quarter. 10.34% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Zacks Investment Research Downgrades Edap Tms (EDAP) to Hold” was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this piece on another site, it was illegally copied and republished in violation of United States and international copyright & trademark law. The correct version of this piece can be viewed at https://www.watchlistnews.com/zacks-investment-research-downgrades-edap-tms-edap-to-hold/1804547.html.

Edap Tms Company Profile

EDAP TMS SA (EDAP) is a holding company engaged in developing and marketing the Ablatherm and Focal One devices. The Company operates two divisions: High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) (including lithotripsy activities). The Company is developing HIFU technology for the treatment of certain other types of tumors.

Get a free copy of the Zacks research report on Edap Tms (EDAP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Edap Tms Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edap Tms and related companies with MarketBeat.com's FREE daily email newsletter.